Virus Diseases
73 treatments and conditions followed through the public trial records. Not medical advice.How a status is set
Lists this condition and the narrower ones beneath it. A condition is not a diagnosis.
Treatments and conditions
| Treatment and condition | Where it stands | Trials |
|---|---|---|
| 9vHPV Vaccine for papillomavirus infections | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| abrysvo for respiratory syncytial virus infections | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| abrysvo + Beyfortus for respiratory syncytial virus infections | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ad26.ZEBOV + MVA-BN-Filo for hemorrhagic fever, ebola | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Amezosvatein Adjuvant Dose Arm D for chickenpox | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Amezosvatein Adjuvant Dose Arm D for herpes zoster | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Amezosvatein Adjuvant Dose Arm F for chickenpox | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Amezosvatein Adjuvant Dose Arm F for herpes zoster | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Amezosvatein Adjuvant Dose Arm H for chickenpox | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Amezosvatein Adjuvant Dose Arm H for herpes zoster | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Amezosvatein Adjuvant Dose Arm J for chickenpox | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Amezosvatein Adjuvant Dose Arm J for herpes zoster | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Amezosvatein Adjuvant Dose Arm L for chickenpox | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Amezosvatein Adjuvant Dose Arm L for herpes zoster | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Amezosvatein Antigen High Dose Arm A for chickenpox | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Amezosvatein Antigen High Dose Arm A for herpes zoster | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Amezosvatein Antigen Low Dose Arm B for chickenpox | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Amezosvatein Antigen Low Dose Arm B for herpes zoster | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ansuvimab for hemorrhagic fever, ebola | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Artesunate for cytomegalovirus infections | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Awake timed prone and repositioning for coronavirus infections | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Beyfortus for respiratory syncytial virus infections | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Biospecimen Collection + Nasal Swab + Survey Administration + REMDESIVIR for respiratory syncytial virus infections | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Circulating Tumor DNA test (ctDNA test) + Dose de-escalation to contralateral neck. + Dose de-escalation to gross disease + Dose de-escalation to gross disease to contralateral neck for papillomavirus infections | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| coadministration for rabies | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| COVID-19 vaccine for rabies | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| CVI-VZV-001 for chickenpox | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| CVI-VZV-001 for herpes zoster | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| dexmedetomidine nasal spray group + long duration high voltage pulse RF therapy group for herpes zoster | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| EGCG and Quinine Sulfate Vaginal Suppository for papillomavirus infections | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ervebo® booster for hemorrhagic fever, ebola | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Fluvoxamine for coronavirus infections | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| High dose Recombinant Trivalent Subunit Rotavirus Vaccine for rotavirus infections | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| High-dose experimental vaccine for herpes zoster | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Hydroxychloroquine for coronavirus infections | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| hydroxychloroquine + azithromycin for coronavirus infections | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| IFN-γ positive selected T-cells for adenoviridae infections | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| IFN-γ positive selected T-cells for cytomegalovirus infections | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Immulina for virus diseases | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Inmazeb for hemorrhagic fever, ebola | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Lb-dtk-mv for cytomegalovirus infections | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Lb-dtk-mv for epstein-barr virus infections | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Low-dose experimental vaccine for herpes zoster | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Mid dose Recombinant Trivalent Subunit Rotavirus Vaccine for rotavirus infections | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| mRNA-1018-H5 for influenza in birds | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Nirsevimab for respiratory syncytial virus infections | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 4 |
| Oxygen-ozone therapy, probiotic supplementation and Standard of care + SivoMixx (200 billion) for coronavirus infections | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| pBI-11 (1 dose) + Placebo (2 doses) for papillomavirus infections | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| pBI-11 (3 doses) for papillomavirus infections | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Placebo for herpes genitalis | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Prone Position for coronavirus infections | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| prone positioning for coronavirus infections | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Prone Positioning (PP) for coronavirus infections | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| rabies vaccine for rabies | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Recombinant varicella zoster virus glycoprotein e antigen for herpes zoster | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 3 |
| RECOMBINANT ZAIRE EBOLAVIRUS KIKWIT-95 ENVELOPE GLYCOPROTEIN MODIFIED VESICULAR STOMATITIS VIRUS for hemorrhagic fever, ebola | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| RSVPreF3 OA investigational vaccine for respiratory syncytial virus infections | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| S-337395 for respiratory syncytial virus infections | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Tetanus-Diphtheria booster for papillomavirus infections | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Tradipitant for coronavirus infections | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| UB-621 high-dose for herpes genitalis | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| UB-621 low-dose for herpes genitalis | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Valganciclovir for cytomegalovirus infections | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Viral Specific T-cells (VSTs) for virus diseases | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| VXA-G1.1-NN for caliciviridae infections | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| VXA-G1.1-NN + VXA-G2.4-NS for caliciviridae infections | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| VXA-G2.4-NS for caliciviridae infections | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Wharton's jelly derived Mesenchymal stem cells. for coronavirus infections | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Wolbachia-infected Aedes aegypti for chikungunya fever | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Wolbachia-infected Aedes aegypti for dengue | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Wolbachia-infected Aedes aegypti for zika virus infection | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Zabdeno® booster for hemorrhagic fever, ebola | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Zelicapavir for respiratory syncytial virus infections | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |